Sort
10,766 grants matching “checkpoint inhibitor”
Immune Checkpoint Inhibitors as Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
$167,292Gerlinde Wernig · Stanford University · K08 · FY2020 · HL
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
$167,278Tyler A Shugg · Indiana University Indianapolis · K23 · FY2023 · GM
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
$167,269Tyler A Shugg · Indiana University Indianapolis · K23 · FY2022 · GM
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
$167,256Tyler A Shugg · Indiana University Indianapolis · K23 · FY2024 · GM
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
$167,256Tyler A Shugg · Indiana University Indianapolis · K23 · FY2025 · GM
A prognostic mRNA immune signature for resected stage II-III melanoma
$167,236Yvonne Margaret Saenger · Columbia University Health Sciences · UH2 · FY2020 · CA
A Strategy for Reactivating p53 in Cancer Stem Cells Using a Novel HdmX Inhibitor
$167,198Mark W Jackson · Case Western Reserve University · R21 · FY2014 · CA
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer
$167,012Adam Joel Bass · Columbia University Health Sciences · P01 · FY2021 · CA
PVSRIPO in melanoma
$166,997Georgia Beasley · Duke University · K08 · FY2021 · CA
A novel IL-2 biologic and tumor immunity
$166,931Thomas R Malek · University Of Miami School Of Medicine · R21 · FY2016 · CA
Investigating multifactorial beta-catenin activation in hepatocellular cancers
$166,859Xin Chen · University Of California, San Francisco · R01 · FY2022 · CA
Modulation of the migratory dendritic cell tumor-immune microenvironment as a novel treatment for SMARCA4-mutant lung adenocarcinoma using combined anti-ICAM1 and anti-PD-L1 therapies
$166,800Matthew D Taylor · Pennsylvania State Univ Hershey Med Ctr · R03 · FY2025 · CA
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer
$166,708Bruce E Clurman · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$166,667Pablo Tamayo · University Of California, San Diego · U01 · FY2019 · CA
Defining PARP Inhibitor Response and Resistance in Prostate Cancer
$166,536Alan Lombard · University Of California At Davis · K01 · FY2023 · CA
Defining PARP Inhibitor Response and Resistance in Prostate Cancer
$166,536Alan Lombard · University Of California At Davis · K01 · FY2024 · CA
Defining PARP Inhibitor Response and Resistance in Prostate Cancer
$166,536Alan Lombard · University Of California At Davis · K01 · FY2022 · CA
Defining PARP Inhibitor Response and Resistance in Prostate Cancer
$166,536Alan Lombard · University Of California At Davis · K01 · FY2021 · CA
Defining PARP Inhibitor Response and Resistance in Prostate Cancer
$166,536Alan Lombard · University Of California At Davis · K01 · FY2025 · CA
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$166,496Theodore S Lawrence · University Of Michigan At Ann Arbor · P50 · FY2013 · CA
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer
$166,357Adam Joel Bass · Columbia University Health Sciences · P01 · FY2023 · CA
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
$166,320Han Zhu · Stanford University · K08 · FY2022 · HL
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
$166,320Han Zhu · Stanford University · K08 · FY2024 · HL
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
$166,320Han Zhu · Stanford University · K08 · FY2023 · HL
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
$166,320Han Zhu · Stanford University · K08 · FY2025 · HL